- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 295/00 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Patent holdings for IPC class C07D 295/00
Total number of patents in this class: 232
10-year publication summary
|
4
|
10
|
8
|
8
|
4
|
5
|
5
|
6
|
1
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Pharmaceutica N.V. | 3394 |
8 |
| Bristol-myers Squibb Company | 4880 |
7 |
| Merck Sharp & Dohme LLC | 3751 |
7 |
| BASF SE | 20940 |
6 |
| Merck Sharp & Dohme Corp. | 2191 |
5 |
| Boehringer Ingelheim International GmbH | 4642 |
5 |
| The Regents of the University of California | 19961 |
4 |
| Enanta Pharmaceuticals, Inc. | 429 |
4 |
| Meiji Seika Pharma Co., Ltd. | 247 |
4 |
| Theravance Biopharma R&D IP, LLC | 456 |
4 |
| The Trustees of Columbia University in the City of New York | 3577 |
3 |
| The Trustees of the University of Pennsylvania | 4323 |
3 |
| Abbvie Inc. | 1800 |
3 |
| Novartis AG | 10744 |
2 |
| Merck Sharp & Dohme B.V. | 708 |
2 |
| Union Carbide Corporation | 259 |
2 |
| Commissariat à l'énergie atomique et aux energies alternatives | 10931 |
2 |
| Cytokinetics, Inc. | 279 |
2 |
| Fondazione Istituto Italiano di Tecnologia | 584 |
2 |
| Gilead Sciences, Inc. | 2032 |
2 |
| Other owners | 155 |